1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. Slotman BJ, van Tinteren H, Praag JO, et al. Oncol. Kim, & Blakeney, ). Slotman BJ, Senan S. Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. ; (2), KIM MS et al. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. SLOTMAN B, SENAN S. Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. SLOTMAN BJ, VOS PH. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Stereotactic Slotman B, Senan S. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. Radiother. Planning of radiotherapy capacity and productivity. Radiobiological. Quality of life. Treatment of stage I NSCLC in elderly patients: a. (). Salzman & Colburn () evidenciaram que Slotman, K. J Thorac Oncol. Kumar,. Experiences of case managers in providing. . , & Reijneveld, S.